Could Clinical Progress With VOQUEZNA Reshape Phathom Pharmaceuticals' Long-Term Strategy (PHAT)? [Yahoo! Finance]
Phathom Pharmaceuticals, Inc. (PHAT)
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
tablets for eosinophilic esophagitis (EoE) in adults, with topline results expected in 2027. This clinical milestone reflects the company's efforts to expand VOQUEZNA's potential indications and address unmet needs in gastrointestinal disorders. We'll now explore how progress in clinical development for VOQUEZNA could shape Phathom Pharmaceuticals' broader investment narrative. The latest GPUs need a type of rare earth metal called Dysprosium and there are only 37 companies in the world exploring or producing it . Find the list for free. Phathom Pharmaceuticals Investment Narrative Recap To be a shareholder in Phathom Pharmaceuticals, you need to believe in the company's ability to expand VOQUEZNA's indications and capture a growing share of GI treatments amid ongoing commercialization in the US. The recent Phase 2 trial launch for EoE is a positive step for the pipeline, but given the timing of results and VOQUEZNA's current exclusivity, it does not materially change the sh
Show less
Read more
Impact Snapshot
Event Time:
PHAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHAT alerts
High impacting Phathom Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PHAT
News
- Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth [Seeking Alpha]Seeking Alpha
- Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)GlobeNewswire
- Phathom Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
- Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at Craig Hallum.MarketBeat
- Phathom Pharmaceuticals (NASDAQ:PHAT) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
PHAT
Earnings
- 10/30/25 - Beat
PHAT
Sec Filings
- 12/2/25 - Form 4
- 11/5/25 - Form 4
- 11/4/25 - Form SCHEDULE
- PHAT's page on the SEC website